Central Nervous System Neoplasms × Gastrointestinal × Clear all
NCT03210714 2026-03-18

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
NCT03213652 2026-03-18

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
13 enrolled
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
NCT03155620 2026-02-10

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,376 enrolled
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT03213704 2025-12-03

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
9 enrolled 12 charts
NCT03157128 2025-10-20

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 3 FDA
NCT03213665 2025-01-27

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 12 charts
NCT03213678 2025-01-27

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 12 charts
NCT03220035 2025-01-27

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
4 enrolled 12 charts
NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled 12 charts
NCT00019630 2024-03-04

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
NCT00007813 2020-02-17

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
21 enrolled
NCT00623077 2017-12-05

MT2004-30: Tomotherapy for Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
23 enrolled
NCT00003926 2017-11-29

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
13 enrolled
NCT00581815 2015-12-28

Spectroscopy With Surface Coils and Decoupling

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
582 enrolled
NCT00024258 2015-11-25

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
22 enrolled 6 charts
NCT00020150 2015-04-29

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
NCT00757614 2013-08-26

Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom

National Cancer Institute (NCI)

Unknown
14,000 enrolled
NCT00003939 2012-09-24

Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
132 enrolled
NCT00030108 2012-03-15

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
30 enrolled
NCT00036959 2012-03-15

ABT-751 in Treating Young Patients With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
90 enrolled
NCT00303940 2012-03-15

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled